MSD Provides Update on European Medicines Agency Marketing Authorisation Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir

MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company’s marketing authorisation application (MAA) for elbasvir/grazoprevir (50mg/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. The CHMP advised MSD that the application will now be reviewed on a standard timetable, rather than the accelerated assessment timeline previously announced. Under the revised timeline, MSD anticipates a European Commission decision in mid-2016.

Merck Honored by R&D Magazine for Innovation

16/12/2015 — DARMSTADT, Germany — (BUSINESS WIRE)
Merck, a leading science and technology company, today announced it has received two prestigious R&D Magazine 100 awards – one for its lab water purification systems, and the other for a technology that allows researchers to investigate scientific questions they previously couldn’t address. “Our researchers are relentlessly curious – aiming to provide the highest quality and most innovative products that solve the toughest problems in life science,” said Udit Batra, President and CEO of the life science business of Merck. “We will continue to drive future advancements within our expansive portfolio. I am most appreciative of our colleagues who have dedicated their careers to these efforts.”